Leidos and the NHL’s Washington Capitals team up to fight cancer
Photo: Jay Townsend
Leidos on Saturday presented Hockey Fights Cancer night for the eighth consecutive season at a sold-out Washington Capitals game at Capital One Arena in Washington, D.C.
The event, part of a National Hockey League (NHL) leaguewide initiative, showcased a number of leading organizations in cancer care and research.
Why you should know: Cancer remains the second-leading cause of death in the U.S. behind heart disease, but cancer deaths have fallen 32% since their peak thanks to organizations that support new treatments and better screening.
During the game, Leidos Health Group President Liz Porter presented a $40,000 donation from the company to support Make-A-Wish® Mid-Atlantic, Pancreatic Cancer Action Network and Leukemia and Lymphoma Society.
From the source: “These are important organizations in the fight against cancer,” says Porter. “Together we’re making unbelievable progress, but there’s still so much work ahead. At Leidos, we’re committed to making sure science wins the fight against this horrible disease.”
Leidos is involved in the fight against cancer on a number of fronts, most notably through Leidos Biomedical Research, which for more than 25 years has partnered with the National Cancer Institute to operate the Frederick National Laboratory for Cancer Research.
- Last week, the company made a large donation to the American Cancer Society to support research in prostate cancer, the second-most common form of cancer among men.
- Last month, Leidos employees participated in the Leukemia & Lymphoma Society’s (LLS) Light the Night event in Reston, Va., where the company also made a large donation.
- The company’s Cancer Advocacy Resource & Emotional Support (CARES) network is a volunteer-led support group for Leidos employees who live with or care for loved ones with cancer.
Cancer will claim more than 600,000 lives this year in the U.S. alone, according to the American Cancer Society, which also estimates nearly two million Americans will receive a new cancer diagnosis in 2022.
Please contact the Leidos media relations team for more information.